An anti-TDP-43 intrabody changed disease-related pathways but did not improve symptoms in ALS mice
Original source
Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
Population inferred from the title and abstract by Compass.
Related topics
An anti-TDP-43 antibody fragment called scFv B1 altered inflammatory and metabolic pathways in cells and in a mouse model of amyotrophic lateral sclerosis (ALS). When given after symptoms began, it did not improve motor behavior or lower plasma neurofilament light chain levels. It did stabilize plasma TDP-43, indicating that it engaged its intended target in the mice.
Why this matters
The findings suggest that targeting TDP-43 can change disease-related biology, but the treatment did not reverse established disease in this preclinical model. This does not change treatment for people with ALS, and it remains unclear whether earlier treatment or combining approaches would provide functional benefit.
Limitations and context
The work was conducted in motor neuron-like cells and transgenic mice, not people. The mouse treatment began after symptoms appeared, and the study found molecular changes without functional improvement. Human safety, dosing, delivery and clinical benefit remain untested.